French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases. The collaboration includes up to $200 million in equity investments, milestone payments, and research and development services through 2018, Sanofi said in a statement.
Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. Shares of SNY traded higher by 0.12% or $0.07/share to $56.18. In the past year, the shares have traded as low as $47.06 and as high as $56.49. On average, 1092610 shares of SNY exchange hands on a given day and today's volume is recorded at 526847.
Source
